Benitec Biopharma Inc. Operating Expenses
Benitec Biopharma Inc. (BNTC) reported Operating Expenses of $51.19 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-09-14
- Benitec Biopharma Inc. operating expenses for the quarter ending 2026-06-30 was $14.43M, a 46.74% increase year-over-year.
- Benitec Biopharma Inc. operating expenses for the quarter ending 2026-03-31 was $13.58M, a 11.43% decline year-over-year.
- Benitec Biopharma Inc. operating expenses for the quarter ending 2025-12-31 was $13.38M, a 23.80% increase year-over-year.
- Benitec Biopharma Inc. operating expenses for the quarter ending 2025-09-30 was $9.80M, a 69.28% increase year-over-year.
- Benitec Biopharma Inc. operating expenses for fiscal 2026 was $51.19M, a 22.57% increase from fiscal 2025.
- Benitec Biopharma Inc. operating expenses for fiscal 2025 was $41.77M, a 85.70% increase from fiscal 2024.
- Benitec Biopharma Inc. operating expenses for fiscal 2024 was $22.49M, a 17.40% increase from fiscal 2023.
- Benitec Biopharma Inc. operating expenses for fiscal 2023 was $19.16M, a 6.86% increase from fiscal 2022.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-14 | $28.01M derived: sum of 2 quarters · filed 2026-09-14 | $41.39M derived: sum of 3 quarters · filed 2026-09-14 | $51.19M 10-K · filed 2026-09-14 | |||
| 2026-03-31 | $13.58M 10-Q · filed 2026-05-14 | $26.96M derived: sum of 2 quarters · filed 2026-05-14 | $36.76M 10-Q · filed 2026-05-14 | $46.60M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2025-12-31 | $13.38M 10-Q · filed 2026-02-12 | $23.18M 10-Q · filed 2026-02-12 | $33.01M derived: sum of 3 quarters · filed 2026-03-20 | $48.35M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2025-09-30 | $9.80M 10-Q · filed 2025-11-14 | $19.64M derived: sum of 2 quarters · filed 2026-03-20 | $34.97M derived: sum of 3 quarters · filed 2026-05-14 | $45.78M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2025-06-30 | $9.83M 10-K/A · filed 2026-03-20 | $25.17M derived: sum of 2 quarters · filed 2026-05-14 | $35.97M derived: sum of 3 quarters · filed 2026-05-14 | $41.77M 10-K · filed 2026-09-14 | |||
| 2025-03-31 | $15.34M 10-Q · filed 2026-05-14 | $10.19M 10-Q · filed 2025-05-14 | $26.14M derived: sum of 2 quarters · filed 2026-05-14 | $31.93M 10-Q · filed 2026-05-14 | $24.59M 10-Q · filed 2025-05-14 | $37.48M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $10.80M 10-Q · filed 2026-02-12 | $8.61M 10-Q · filed 2025-02-14 | $16.60M 10-Q · filed 2026-02-12 | $14.40M 10-Q · filed 2025-02-14 | $22.14M derived: sum of 3 quarters · filed 2026-03-20 | $26.29M derived: sum of 4 quarters · filed 2026-03-20 | |
| 2024-09-30 | $5.79M 10-K/A · filed 2026-03-20 | $11.34M derived: sum of 2 quarters · filed 2026-03-20 | $15.48M derived: sum of 3 quarters · filed 2026-03-20 | $22.41M derived: sum of 4 quarters · filed 2026-03-20 | |||
| 2024-06-30 | $5.55M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-20 | $9.69M derived: sum of 2 quarters · filed 2026-03-20 | $16.62M derived: sum of 3 quarters · filed 2026-03-20 | $22.49M 10-K/A · filed 2026-03-20 | |||
| 2024-03-31 | $4.14M 10-Q · filed 2025-05-14 | $11.07M derived: sum of 2 quarters · filed 2025-05-14 | $16.94M 10-Q · filed 2025-05-14 | $21.50M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $6.93M 10-Q · filed 2025-02-14 | $12.80M 10-Q · filed 2025-02-14 | $17.36M derived: sum of 3 quarters · filed 2025-02-14 | $21.75M derived: sum of 4 quarters · filed 2025-02-14 | |||
| 2023-09-30 | $5.87M 10-Q · filed 2024-11-14 | $10.43M derived: sum of 2 quarters · filed 2024-11-14 | $14.83M derived: sum of 3 quarters · filed 2024-11-14 | $20.45M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $4.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $8.95M derived: sum of 2 quarters · filed 2024-09-26 | $14.58M derived: sum of 3 quarters · filed 2024-09-26 | $19.16M 10-K · filed 2024-09-26 | |||
| 2023-03-31 | $4.39M 10-Q · filed 2024-05-13 | $10.02M derived: sum of 2 quarters · filed 2024-05-13 | $14.60M 10-Q · filed 2024-05-13 | $19.34M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $5.62M 10-Q · filed 2024-02-13 | $10.20M 10-Q · filed 2024-02-13 | $14.94M derived: sum of 3 quarters · filed 2024-02-13 | $18.45M derived: sum of 4 quarters · filed 2024-02-13 | |||
| 2022-09-30 | $4.58M 10-Q · filed 2023-11-13 | $9.32M derived: sum of 2 quarters · filed 2023-11-13 | $12.83M derived: sum of 3 quarters · filed 2023-11-13 | $17.69M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $4.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-21 | $8.25M derived: sum of 2 quarters · filed 2023-09-21 | $13.11M derived: sum of 3 quarters · filed 2023-09-21 | $17.93M 10-K · filed 2023-09-21 | |||
| 2022-03-31 | $3.51M 10-Q · filed 2023-05-15 | $8.37M derived: sum of 2 quarters · filed 2023-05-15 | $13.19M 10-Q · filed 2023-05-15 | $17.05M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $4.86M 10-Q · filed 2023-02-13 | $9.68M 10-Q · filed 2023-02-13 | $13.54M derived: sum of 3 quarters · filed 2023-02-13 | $17.33M derived: sum of 4 quarters · filed 2023-02-13 | |||
| 2021-09-30 | $4.82M 10-Q · filed 2022-11-10 | $8.68M derived: sum of 2 quarters · filed 2022-11-10 | $12.47M derived: sum of 3 quarters · filed 2022-11-10 | $15.73M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-02 | $7.65M derived: sum of 2 quarters · filed 2022-09-02 | $10.91M derived: sum of 3 quarters · filed 2022-09-02 | $13.65M 10-K · filed 2022-09-02 | |||
| 2021-03-31 | $3.79M 10-Q · filed 2022-05-16 | $7.05M derived: sum of 2 quarters · filed 2022-05-16 | $9.80M 10-Q · filed 2022-05-16 | $12.65M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $3.26M 10-Q · filed 2022-02-14 | $6.00M 10-Q · filed 2022-02-14 | $8.86M derived: sum of 3 quarters · filed 2022-02-14 | $11.00M derived: sum of 4 quarters · filed 2022-02-14 | |||
| 2020-09-30 | $2.75M 10-Q · filed 2021-11-15 | $5.60M derived: sum of 2 quarters · filed 2021-11-15 | $7.74M derived: sum of 3 quarters · filed 2021-11-15 | $9.92M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-20 | $4.99M derived: sum of 2 quarters · filed 2021-09-20 | $7.18M derived: sum of 3 quarters · filed 2021-09-20 | $8.38M 10-K · filed 2021-09-20 | |||
| 2020-03-31 | $2.14M 10-Q · filed 2021-05-12 | $4.33M derived: sum of 2 quarters · filed 2021-05-12 | $5.53M 10-Q · filed 2021-05-12 | ||||
| 2019-12-31 | $2.19M 10-Q · filed 2021-02-09 | $3.39M 10-Q · filed 2021-02-09 | |||||
| 2019-09-30 | $1.20M 10-Q · filed 2020-11-13 | ||||||
| 2019-06-30 | $9.62M 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |